Clinical trials
Tolerance clinical trials
Below are recruiting tolerance clinical trials, each written for real people, not researchers. We’re tracking 953 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07321106RecruitingPhase 1
CBI-1214 for advanced colorectal cancer
This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07682896RecruitingPhase 2
Testing YB-101 for safety and effectiveness in Graves' disease
This trial tests an investigational drug called YB-101 for people with Graves' disease, whether or not they have thyroid eye disease. The goal is to see if the drug is safe and can help.
Gilbert, ArizonaAges 18 years+ - NCT07228364RecruitingPhase 1
Testing safety of AZD1613 for polycystic kidney disease
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
Birmingham, AlabamaAges 18–65 - NCT06475742Enrolling by invitationPhase 3
Long-term safety of cenerimod in lupus patients
This study tests the long-term safety of a drug called cenerimod for people with lupus (SLE) who have already completed a 12-month study of the same drug. It helps researchers see if the medicine stays safe and tolerable over a longer period.
Aurora, ColoradoAges 18–75 - NCT07369154RecruitingPhase 3
Safety of a long-term schizophrenia treatment
This study tests the long-term safety of an investigational medication for schizophrenia over one year. It may be an option if you are currently stable on your antipsychotic medication.
Chandler, ArizonaAges 18–65 - NCT07490951Recruiting
CAR-T cell therapy for refractory autoimmune diseases
This trial tests a personalized cell therapy (CAR-T cells that target CD19 and BCMA proteins) for people with lupus, Sjogren's, scleroderma, dermatomyositis, antisynthetase syndrome, immune-mediated necrotizing myopathy, rheumatoid arthritis, or ANCA-associated vasculitis that has not responded to standard treatments. The goal is to see if this therapy can reduce disease activity.
Wuhan, HubeiAges 18–70 - NCT06714006RecruitingPhase 1
Testing safety of PYC-003 for ADPKD
This study is testing a new investigational medicine called PYC-003 for people with autosomal dominant polycystic kidney disease (ADPKD). It is one of the first studies in humans, so the main goal is to see if the medicine is safe and tolerable. The study is for people with a specific genetic cause (PKD1 mutation) and with certain kidney imaging types.
Southport, Gold CoastAges 18–65 - NCT07184502RecruitingPhase 1
Testing a new injection for weight loss in healthy and overweight adults
This trial tests an investigational injection called ZT003 to see if it is safe and how the body processes it. It is for healthy volunteers or those who are overweight or obese, to help understand how this treatment might work.
Brisbane, QueenslandAges 18–65 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT06699771RecruitingPhase 1
Safety study of GCC2005 for NK and T-cell cancers
This trial tests a new drug called GCC2005 for people with certain types of NK or T-cell cancers that have come back or not responded to at least two previous treatments. The goal is to see if it is safe and if it can help shrink tumors.
Seoul, SeoulAges 19–80 - NCT07724340RecruitingPhase 2
Study of AT673 plus semaglutide for type 2 diabetes and weight loss
This study tests a new medication called AT673 combined with semaglutide (Wegovy) to help people with type 2 diabetes and overweight or obesity lose weight and improve blood sugar. It is for people who have tried diet and exercise to lose weight but haven't had success.
Chandler, ArizonaAges 18 years+ - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+ - NCT07726147RecruitingPhase 1
Testing a new allergy shot for Japanese cedar pollen
This trial tests a new allergy shot (ITI-9001) for people with Japanese cedar pollen allergy. It aims to see if the shot is safe and can reduce allergy symptoms. The study is for people who have not tried immunotherapy before.
Tokyo, Shinjuku-kuAges 1.5 years–65 years - NCT07673120RecruitingPhase 1
Safety study of ABBV-313 in healthy adults
This study tests a new drug called ABBV-313 in healthy adults to see if it is safe and how the body handles it. You will receive either a single injection or infusion, or multiple doses, to help researchers understand its effects.
Grayslake, IllinoisAges 18–55 - NCT06966401RecruitingPhase 3
Long-term safety study of a new depression treatment
This study tests a new oral medication (NBI-1065845) added to your current antidepressant to see if it's safe and tolerable over a long period for people with depression that hasn't fully responded to treatment.
Huntsville, AlabamaAges 18 years+ - NCT06712355RecruitingPhase 3
Testing an experimental drug with chemo for newly diagnosed extensive-stage small cell lung cancer
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
Tucson, ArizonaAges 18 years+ - NCT06597006RecruitingPhase 3
Study of inclisiran for children with homozygous familial high cholesterol
This trial tests a new medicine called inclisiran to lower very high cholesterol in children aged 2 to 12 who have a specific genetic condition (homozygous familial hypercholesterolemia, or HoFH). You may not need to change your current cholesterol treatments, and the study will check if inclisiran can help reduce your LDL cholesterol further.
San Francisco, CaliforniaAges 2–11 - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Athens, GeorgiaAges 18 years+ - NCT07693231RecruitingPhase 1
Study of BI 3034701 for healthy or overweight Japanese people
This trial tests different doses of a new medicine in healthy Japanese people and those with obesity or overweight. It aims to see how well the body handles the drug and if it is safe.
Fukuoka, FukuokaAges 18–64 - NCT07399678RecruitingPhase 1
A study of ALV-100 for overweight people with or without type 2 diabetes
This trial tests a new medication called ALV-100 for safety and how well it works in people who are overweight or have type 2 diabetes. It might help if you have a higher body weight and want to try a new treatment option.
Miami, FloridaAges 18–65 - NCT07271693RecruitingPhase 1
Safety study of a new medicine in healthy volunteers
This trial tests a new medicine called RO7806881 in healthy volunteers to see if it is safe, what dose is best, and how the body handles it. It is an early study that helps researchers decide if the drug should be tested in people with a disease.
ChristchurchAges 18–50 - NCT07721597RecruitingEarly Phase 1
Testing ZP6590 in Men of Various Weights
This trial tests an experimental medication called ZP6590 given as injections. It's for men who are at a normal weight, overweight, or have obesity, and studies how safe and well-tolerated the drug is in different doses.
Neuss, North Rhine-WestphaliaAges 18–60 - NCT07575399RecruitingPhase 3
Switching to a New Weight-Loss Medication From Current GLP-1
This trial tests whether switching from your current GLP-1 medication (like Ozempic or Wegovy) to a new drug called maridebart cafraglutide works as well or better for weight management. You must have already lost at least 10% of your body weight on your current GLP-1 and be doing well with it.
Pelham, AlabamaAges 18–99 - NCT07491172RecruitingPhase 1
Trial of CTX310 for stubborn high cholesterol and fats
This trial tests a new medicine, CTX310, for people with persistently high levels of fats (triglycerides) and cholesterol that have not improved with standard treatments. It aims to see if the drug is safe and tolerable.
Hialeah, FloridaAges 18–75
Hear when a new Tolerance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tolerance?
- Yes. Clin2 currently lists 953 recruiting tolerance studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tolerance trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tolerance trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.